Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment
2015; BMJ; Volume: 74; Issue: 12 Linguagem: Inglês
10.1136/annrheumdis-2015-207978
ISSN1468-2060
AutoresDer-Yuan Chen, Yi‐Ming Chen, Wei‐Ting Hung, Hsin‐Hua Chen, Chia-Wei Hsieh, Yi‐Hsing Chen, Wen‐Nan Huang, Tsu‐Yi Hsieh,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoGolimumab, a fully humanised antitumour necrosis factor (anti-TNF)-α monoclonal antibody, has been proven effective in the treatment of both rheumatoid arthritis (RA)1 and ankylosing spondylitis (AS).2 As with other anti-TNF-α inhibitors, golimumab may elicit antidrug antibodies (ADAb), leading to pharmacokinetic changes.3 ,4 With the limited data regarding the immunogenicity of golimumab,1 ,2 ,5 we aim to evaluate the relations among ADAb, serum drug trough levels, therapeutic response and methotrexate (MTX) dosage in golimumab-treated patients. We initially enrolled 78 biologic-naive patients who started golimumab therapy at a dosage of 50 mg given subcutaneously once a month. Two patients with AS were lost to follow-up due to skin reactions at the 2nd and 3rd month, respectively. Hence, the remaining 76 patients (33 RA and 43 AS) completed the 24-week treatment course, and were eligible for this study. Serum ADAb levels and drug trough levels were determined at week 24 of golimumab therapy by bridging ELISA and capture ELISA (Progenika Biopharma SA, Derio, Spain), respectively, a modified version of the method used in our previous study.6 A positive ADAb result was defined as a titre >30 arbitrary unit/mL in combination with a golimumab level <5.0 μg/mL. Because all of the enrolled patients were …
Referência(s)